Form 8-K Kiniksa Pharmaceuticals For: Jan 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Goldman Sachs Reiterates Buy Rating on Kiniksa (KNSA)
January 13, 2025 8:48 AM ESTGoldman Sachs analyst Paul Choi reiterated a Buy rating and $32.00 price target on Kiniksa (NASDAQ: KNSA)
The analyst comments "Preliminary FY24 Arcalyst revenue results deliver a slight beat with FY25 guidance modestly ahead of consensus. Ahead of a major industry conference, KNSA reported preliminary FY24... More
